Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LWP779 Phase 1 in Healthy Participants
NCT07371455Phase 1Recruiting
- Sponsor
- Longwood Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LWP779 in ischemic stroke (5 arms), sponsored by Longwood Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at Day 16, 12-lead electrocardiogram QT Interval at Day 16 and 5 more. Started Mar 2026; status: recruiting.
02
Drugs
LWP779
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07371455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371455.